Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

Published:2022-10-19 Issue:1 Volume:64 Page:234-237
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gardenswartz Aliza¹,Mehta Brinda²,El-Mallawany Nader Kim³,van de Ven Carmella¹^ORCID,Hochberg Jessica¹,Flower Allyson⁴,Morris Erin¹,Harrison Lauren¹,Chu Yaya¹,Basso Jaclyn¹,Gerard Perry⁵,Islam Humayun⁶,Ayello Janet¹,Baxter-Lowe Lee Ann⁷,Cairo Mitchell S.¹⁶⁸⁹¹⁰^ORCID

Affiliation:

1. Department of Pediatrics, New York Medical College, Valhalla, NY, USA

2. Department of Pediatrics, St. Jude Children’s Research Hospital, Peoria, IL, USA

3. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

5. Department of Radiology, New York Medical College, Valhalla, NY, USA

6. Department of Pathology, New York Medical College, Valhalla, NY, USA

7. Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles, Los Angeles, CA, USA

8. Department of Medicine, New York Medical College, Valhalla, NY, USA

9. Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA

10. Department of Cell Biology and Anatomy, Hematology and Stem Cell Transplantation, Valhalla, NY, USA

Funder

Pediatric Cancer Research Foundation, Pediatric Cancer Foundation, and the St. Baldrick’s Foundation and the Marisa Fund

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2133542

Reference15 articles.

1. Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study

2. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

3. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

4. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults;Journal of the National Comprehensive Cancer Network;2024-07